5 assets in Adrenal Gland Pheochromocytoma

Therapeutic assets addressing Adrenal Gland Pheochromocytoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- Adrenal Gland Pheochromocytoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Adrenal Gland Pheochromocytoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Adrenal Gland Pheochromocytoma	National Cancer Institute (NCI)	P2	CCC (53)
Pembrolizumab Adrenal Gland Pheochromocytoma	M.D. Anderson Cancer Center	P2	CCC (53)
Talazoparib Adrenal Gland Pheochromocytoma	National Cancer Institute (NCI)	P2	CCC (53)